SG11201908691PA - Compounds and methods for the treatment of parasitic diseases - Google Patents
Compounds and methods for the treatment of parasitic diseasesInfo
- Publication number
- SG11201908691PA SG11201908691PA SG11201908691PA SG11201908691PA SG 11201908691P A SG11201908691P A SG 11201908691PA SG 11201908691P A SG11201908691P A SG 11201908691PA SG 11201908691P A SG11201908691P A SG 11201908691PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- cambridge
- treatment
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473771P | 2017-03-20 | 2017-03-20 | |
| PCT/US2018/023270 WO2018175385A1 (en) | 2017-03-20 | 2018-03-20 | Compounds and methods for the treatment of parasitic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908691PA true SG11201908691PA (en) | 2019-10-30 |
Family
ID=63586520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908691P SG11201908691PA (en) | 2017-03-20 | 2018-03-20 | Compounds and methods for the treatment of parasitic diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11174260B2 (es) |
| EP (1) | EP3600286B1 (es) |
| JP (1) | JP7306997B2 (es) |
| KR (1) | KR20190129968A (es) |
| CN (1) | CN110650738B (es) |
| AU (1) | AU2018240031B2 (es) |
| BR (1) | BR112019019494A2 (es) |
| CA (1) | CA3057087A1 (es) |
| CO (1) | CO2019011546A2 (es) |
| ES (1) | ES2966369T3 (es) |
| IL (1) | IL269390B (es) |
| MX (1) | MX2019011271A (es) |
| MY (1) | MY197171A (es) |
| PH (1) | PH12019502150A1 (es) |
| SG (1) | SG11201908691PA (es) |
| WO (1) | WO2018175385A1 (es) |
| ZA (1) | ZA201906213B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201908691PA (en) | 2017-03-20 | 2019-10-30 | Broad Inst Inc | Compounds and methods for the treatment of parasitic diseases |
| CN110168093B (zh) * | 2017-09-12 | 2023-08-15 | 中科蓝华(广州)生物医药技术有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| WO2020041384A1 (en) * | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
| US20220033404A1 (en) * | 2018-09-18 | 2022-02-03 | Washington University | Treatment of infections of toxoplasma gondii and closely related parasites |
| EP3908587B1 (en) | 2019-01-09 | 2024-05-22 | Eisai R&D Management Co., Ltd. | Method for synthesis of diazabicyclo[6.2.0]decane related compounds |
| US20230009323A1 (en) * | 2019-10-25 | 2023-01-12 | The Broad Institute, Inc. | Compounds and methods for the treatment of cryptosporidiosis |
| WO2022067060A1 (en) * | 2020-09-24 | 2022-03-31 | The Broad Institute, Inc. | Apicomplexan parasite inhibition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3176017A (en) * | 1963-02-26 | 1965-03-30 | American Home Prod | Aroylalkyl derivatives of diazabicyclo-nonanes and-decanes |
| US3542780A (en) | 1967-07-25 | 1970-11-24 | American Home Prod | 2-amidino-1,2,3,4-tetrahydropyrazine(1,2-a)indoles |
| US3531485A (en) | 1967-08-14 | 1970-09-29 | American Home Prod | Aryl-substituted diazabicycloalkanes |
| YU2101A (sh) | 1998-07-14 | 2005-06-10 | Bayer Aktiengesellschaft | Antiparazitski derivati artemisinina (endoperoksidi) |
| UA77515C2 (en) | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
| EP1698375B1 (en) | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
| CN105164124B (zh) * | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
| SG10201703094UA (en) | 2012-12-20 | 2017-06-29 | Ucb Biopharma Sprl | Therapeutically active pyrazolo-pyrimidine derivatives |
| UY35772A (es) | 2013-10-14 | 2015-05-29 | Bayer Cropscience Ag | Nuevos compuestos plaguicidas |
| GB2533536B (en) | 2013-10-24 | 2021-05-19 | Toyota Motor Co Ltd | Cathode active material for sodium batteries, and sodium battery |
| JP6591429B2 (ja) | 2013-11-11 | 2019-10-16 | ザ・ブロード・インスティテュート・インコーポレイテッド | マラリアの治療のための化合物及び方法 |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| LT3122745T (lt) | 2014-03-24 | 2019-04-10 | Novartis Ag | Monobaktamo organiniai junginiai, skirti bakterinių infekcijų gydymui |
| SI3210973T1 (sl) | 2014-10-24 | 2021-04-30 | Takeda Pharmaceutical Company Limited | Heteroarilne spojine za zdravljenje oftalmičnih bolezni |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| SG11201908691PA (en) | 2017-03-20 | 2019-10-30 | Broad Inst Inc | Compounds and methods for the treatment of parasitic diseases |
| US20220033404A1 (en) | 2018-09-18 | 2022-02-03 | Washington University | Treatment of infections of toxoplasma gondii and closely related parasites |
| WO2020219610A1 (en) | 2019-04-23 | 2020-10-29 | Washington University | Compounds and methods for the treatment of parasitic diseases |
-
2018
- 2018-03-20 SG SG11201908691P patent/SG11201908691PA/en unknown
- 2018-03-20 JP JP2019551706A patent/JP7306997B2/ja active Active
- 2018-03-20 MX MX2019011271A patent/MX2019011271A/es unknown
- 2018-03-20 MY MYPI2019005496A patent/MY197171A/en unknown
- 2018-03-20 US US16/495,357 patent/US11174260B2/en active Active
- 2018-03-20 CN CN201880033124.6A patent/CN110650738B/zh active Active
- 2018-03-20 IL IL269390A patent/IL269390B/en unknown
- 2018-03-20 EP EP18771869.7A patent/EP3600286B1/en active Active
- 2018-03-20 WO PCT/US2018/023270 patent/WO2018175385A1/en unknown
- 2018-03-20 BR BR112019019494A patent/BR112019019494A2/pt unknown
- 2018-03-20 CA CA3057087A patent/CA3057087A1/en active Pending
- 2018-03-20 ES ES18771869T patent/ES2966369T3/es active Active
- 2018-03-20 AU AU2018240031A patent/AU2018240031B2/en active Active
- 2018-03-20 KR KR1020197030814A patent/KR20190129968A/ko not_active Application Discontinuation
-
2019
- 2019-09-19 ZA ZA2019/06213A patent/ZA201906213B/en unknown
- 2019-09-19 PH PH12019502150A patent/PH12019502150A1/en unknown
- 2019-10-17 CO CONC2019/0011546A patent/CO2019011546A2/es unknown
-
2021
- 2021-07-28 US US17/387,639 patent/US11866441B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019132950A3 (es) | 2021-06-29 |
| US11174260B2 (en) | 2021-11-16 |
| KR20190129968A (ko) | 2019-11-20 |
| MX2019011271A (es) | 2020-01-20 |
| CN110650738B (zh) | 2023-05-09 |
| EP3600286A4 (en) | 2020-12-02 |
| CN110650738A (zh) | 2020-01-03 |
| RU2019132950A (ru) | 2021-04-21 |
| US20200095253A1 (en) | 2020-03-26 |
| CA3057087A1 (en) | 2018-09-27 |
| CO2019011546A2 (es) | 2020-02-28 |
| ZA201906213B (en) | 2022-03-30 |
| US11866441B2 (en) | 2024-01-09 |
| IL269390A (en) | 2019-11-28 |
| JP2020514381A (ja) | 2020-05-21 |
| MY197171A (en) | 2023-05-28 |
| US20220162211A1 (en) | 2022-05-26 |
| WO2018175385A1 (en) | 2018-09-27 |
| EP3600286B1 (en) | 2023-08-16 |
| ES2966369T3 (es) | 2024-04-22 |
| JP7306997B2 (ja) | 2023-07-11 |
| BR112019019494A2 (pt) | 2020-04-28 |
| EP3600286A1 (en) | 2020-02-05 |
| IL269390B (en) | 2022-08-01 |
| AU2018240031B2 (en) | 2022-07-14 |
| AU2018240031A1 (en) | 2019-10-10 |
| PH12019502150A1 (en) | 2020-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11202000325UA (en) | Selective inhibitors of nlrp3 inflammasome | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents |